Bicitropeptide powder and placebo in the treatment of duodenal ulcers. A double-blind endoscopically controlled clinical trial.

Abstract

In a double-blind study comprising 50 patients with endoscopically proven uncomplicated duodenal ulcers a powder formulation of bicitropeptide (BCP-Compound) was found to be superior to placebo. On endoscopic examination 19 patients (76%) treated with bicitropeptide powder had healed, while 3 (12%) showed some degree of healing, a total success rate of 88%. Only 5 patients (20%) on placebo had healed completely while 3 (12%) showed some degree of healing (chi 2 = 17,9667; P less than 0,0005). Blood and urine bismuth levels were measured before and after 6 and 12 weeks of therapy, and showed an increase after the first 6 weeks. By 12 weeks the levels had decreased, although they were still higher than the initial values. The blood levels were, however, significantly lower than postulated toxic levels.

• Authors: M G Moshal, J M Spitaels, R Bhoola, H van Leenhoff, F Khan
• Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (S Afr Med J) Vol. 61 Issue 7 Pg. 234-5 (Feb 13 1982) ISSN: 0256-9574 [Print] South Africa
• PMID: 7036376 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Ulcer Agents
• Metalloproteins
• Proteins
• bicitropeptide
• Bismuth

Topics

• Adult
• Anti-Ulcer Agents (therapeutic use)
• Bismuth (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Duodenal Ulcer (drug therapy)
• Humans
• Metalloproteins
• Proteins (therapeutic use)